New checkpoint inhibitor on the block
Researchers at Austrian IMBA have identified a well-known co-factor of amino acid synthesis and monoamine neurotransmitter synthesis to play a prominent role in the development of autoimmunity and cancer.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
BIO-Europe: advanced therapies in focus
/in News/by Thomas GabrielczykGene and cell therapies, pediatric drugs, and formulation were just some hot topics discussed in a record number of B2B meetings at BIO-Europe in Copenhagen.
Dry AMD: Oxurion licences heparanase blockers from Beta Therapeutics
/in News/by Thomas GabrielczykOxurion NV and Beta Therapeutics Inc have inked an R&D agreement aimed to develop new heparanase inhibitors to treat dry AMD.
Nanobots heading to eye delivery
/in News/by Thomas GabrielczykGerman researchers have developed a drug delivery nanobot that can propel through the eye.
Argenx antibody kills AML
/in News/by Thomas GabrielczykArgenx SE announced it achieved an overall response rate of 92% in patients with AML with its anti-TNFSF7 (CD70) antibody cusatuzumab.
Sanofi and Denali Therapeutics ink 1.125bn deal in neurology/inflammation
/in News/by Thomas GabrielczykSanofi has acquired the global commercialisation rights for two preclinical programmes from Denali Therapeutics.
ProQR in licence deal with Ionis Pharmaceuticals
/in News/by Thomas GabrielczykDutch ProQR NV has licensed global commercialisation rights to IONIS-RHO-2.5Rx (QR-1123) from Ionis Pharmaceuticals, to treat autosomal dominant retinitis pigmentosa (adRP)
Newron bags 40m EIB loan
/in News/by Thomas GabrielczykThe EIB has agreed to support Italian CNS drug developer Newron Pharmaceuticals with up to 40m to support the development of the company’s late-stage pipeline.
TES Pharma presents new treatment approach towards AKI and NALFD
/in News/by Thomas GabrielczykTES Pharma has presented a novel treatment approach for acute kidney injury and non-alcoholic fatty liver disease in Nature.
MEPs vote for ban of single-use plastics
/in News/by Thomas GabrielczykThe European Parliament has approved measures that could lead to a ban of the top 10 single use plastic products that contribute to marine littering by 2021.